On 19 June 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, intended for treatment of adults and adolescents infected with human immunodeficiency virus type 1 (HIV-1). The applicant for this medicinal product is Viatris Limited.
Access the full overview here.
Source : European Medicines Agency
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.